Earnings summaries and quarterly performance for Zai Lab.
Executive leadership at Zai Lab.
Board of directors at Zai Lab.
Research analysts who have asked questions during Zai Lab earnings calls.
AR
Anupam Rama
JPMorgan Chase & Co.
4 questions for ZLAB
Also covers: APLS, BBIO, BOLD +16 more
JC
Jonathan Chang
Leerink Partners
4 questions for ZLAB
Also covers: ADAP, GMAB, IMCR +10 more
YN
Yigal Nochomovitz
Citigroup Inc.
4 questions for ZLAB
Also covers: ALDX, APLS, ARCT +22 more
LW
Li Wang Watsek
Cantor Fitzgerald
3 questions for ZLAB
Also covers: AFMD, ALXO, ARVN +7 more
Michael Yee
Jefferies
3 questions for ZLAB
Also covers: ALLO, AMGN, BEAM +14 more
Linhai Zhao
Goldman Sachs
2 questions for ZLAB
LC
Louise Chen
Cantor Fitzgerald
2 questions for ZLAB
Also covers: ARDX, CNTB, IMAB +15 more
PH
Po Han Lin
Morgan Stanley
2 questions for ZLAB
JL
Jack Lin
Morgan Stanley
1 question for ZLAB
LH
Lin Hisao
Goldman Sachs
1 question for ZLAB
RL
Rebecca Liang
Sanford C. Bernstein & Co.
1 question for ZLAB
Ziyi Chen
Goldman Sachs & Co.
1 question for ZLAB
Also covers: BGNE, LEGN, ONC
Recent press releases and 8-K filings for ZLAB.
Zai Lab Highlights Strong Financial Position and Pipeline Progress at JPMorgan Healthcare Conference
ZLAB
Product Launch
New Projects/Investments
Guidance Update
- Zai Lab reported a strong cash position of $817 million as of September 2025 and a profitable China commercial business with sales around $460 million, providing a financial foundation for the company.
- In China, the company recently received approval for Cobenfy for schizophrenia, with a launch planned for the first half of 2026 and an NRDL listing target of 2027, while Vyvgart is expected to be a top-line growth driver in 2026 and beyond.
- Zai Lab's lead global asset, ZOSI (DLL3-focused ADC) for small cell lung cancer, has a Phase III trial underway (initiated Q4 2025) with potential for accelerated approval in the U.S. as early as 2028.
- Further global pipeline advancements include the IL-13/31 (1503) program for atopic dermatitis (Phase I data by end of 2027) and the planned initiation of a Phase I study for LRC-15 ADC in solid tumors in 2026.
- The company emphasizes leveraging its China expertise for efficient R&D and expects modest R&D growth in the near term, with tightly managed SG&A, leading to a clear path to profitability.
Jan 13, 2026, 11:00 PM
ZLAB Highlights Strong Financial Position and Global Pipeline at J.P. Morgan Healthcare Conference
ZLAB
New Projects/Investments
Product Launch
Guidance Update
- ZLAB reported a robust cash position of $817.2 million as of September 30, 2025, and is focused on near-term margin expansion and a path toward profitability.
- The company anticipates its first U.S. approval by 2028, with its lead asset, Zoci (DLL3 ADC), in a pivotal study demonstrating potential best-in-class efficacy and safety.
- ZLAB is expanding its global pipeline with over 9 indications in development by 2030 and expects a catalyst-rich year in 2026, including global phase 1 data for Zoci and potential China approval for TIVDAK.
Jan 13, 2026, 11:00 PM
Zai Lab Highlights Profitable China Business and Advancing Global Pipeline at JPMorgan Conference
ZLAB
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Zai Lab's China commercial business is profitable and growing, with eight products approved and sales "headed towards somewhere around $460 million". This business provides a strong financial foundation, contributing to a cash position of $817 million as of September.
- The company is advancing its global pipeline, notably with its DLL3-focused ADC (Zoci/ZL-1310) for small cell lung cancer, which has a potential for accelerated approval as early as 2028 in the U.S..
- Recent commercial successes in China include the 2025 listing of VYVGART for gMG as a preferred agent and the recent approval of COBENFY for schizophrenia, which will launch in the first half of 2026 with an eye towards NRDL listing in 2027.
- Zai Lab operates with a "dual engine" strategy, leveraging its China commercial capabilities to fund and accelerate a global R&D pipeline focused on immunology and oncology, aiming for double-digit growth in China through the end of the decade.
Jan 13, 2026, 11:00 PM
Zai Lab Highlights Dual Engine Strategy, Strong Financials, and Pipeline Progress at JPMorgan Conference
ZLAB
Product Launch
New Projects/Investments
Guidance Update
- Zai Lab operates with a dual engine strategy, utilizing its profitable and growing China commercial business (generating approximately $460 million in sales from eight approved products) to fund its global pipeline.
- The company maintains a strong financial position with $817 million in cash as of September 2025, demonstrating a path to profitability and modest cash burn.
- Significant pipeline progress includes the DLL3-focused ADC (ZOSI), currently in a global Phase III trial for small cell lung cancer, with potential for accelerated U.S. approval as early as 2028.
- Further pipeline developments include the IL-13/31 program for atopic dermatitis (Phase I data expected by end of 2027) and the initiation of a Phase I study for LRC-15 ADC in solid tumors this year.
- In its China commercial segment, Zai Lab is driving growth with Vyvgart and preparing for the launch of Cobenfy (approved for schizophrenia) in the first half of 2026, targeting NRDL listing in 2027.
Jan 13, 2026, 11:00 PM
Zai Lab Highlights 2026 Strategic Priorities and Global Pipeline Progress
ZLAB
New Projects/Investments
Product Launch
Guidance Update
- Zai Lab presented its 2026 strategic priorities and clinical development progress at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
- Zocilurtatug pelitecan (Zoci), a lead global asset, is expected to be in three registrational studies by the end of 2026, including a Phase 3 study initiated for 2L/3L SCLC.
- The company anticipates the commercial launch of COBENFY in China in 1H 2026.
- Zai Lab expects to advance multiple other global oncology and immunology assets into clinical development in 2026, including ZL-6201 (global Phase 1 initiation in 1Q 2026) and ZL-1311 (entering global clinical development).
Jan 13, 2026, 1:00 PM
Zai Lab Receives China Approval for Schizophrenia Therapy COBENFY
ZLAB
Product Launch
New Projects/Investments
- Zai Lab announced the NMPA approval of COBENFY (xanomeline and trospium chloride) for the treatment of schizophrenia in adults in China.
- COBENFY is a first-in-class therapy and the first schizophrenia treatment with a novel mechanism of action approved in over 70 years, offering a new approach to treating the disorder.
- The therapy has been included in China’s national-level schizophrenia treatment guidelines and targets approximately 8 million adults living with schizophrenia in China.
Dec 23, 2025, 12:30 PM
Zai Lab Secures 2025 NRDL Renewals for Key Medications
ZLAB
Product Launch
New Projects/Investments
- Zai Lab has secured the renewal of VYVGART, NUZYRA (oral formulation), and ZEJULA in China's 2025 National Reimbursement Drug List (NRDL), expanding patient access and bringing its total NRDL-listed products to six.
- The company reported $441.63 million in revenue with a three-year revenue growth rate of 37.5%, but faces profitability challenges with a negative EPS of -1.9, an operating margin of -50.32%, and a net margin of -46.83%.
- Zai Lab's market capitalization is approximately $2.22 billion, with a beta of 0.77, suggesting lower volatility compared to the broader market.
Dec 7, 2025, 5:17 AM
Zai Lab Reports Q3 2025 Results, Updates Full-Year Revenue Guidance
ZLAB
Earnings
Guidance Update
New Projects/Investments
- Zai Lab reported Q3 2025 total revenue of $116.1 million, a 14% year-over-year increase, and an adjusted loss from operations of $28 million, a 42% improvement from the prior year.
- The company updated its full-year total revenue guidance to at least $460 million and now expects profitability to shift beyond the fourth quarter of 2025.
- Performance of key products like Vyvgart and Zejula has been slower than expected due to market dynamics and competition, while XACDURO faces supply constraints.
- Zai Lab's global pipeline is advancing, with ZL1310 (Josie) entering a pivotal Phase 3 trial for small cell lung cancer, aiming for global approval by 2027 or early 2028.
Nov 6, 2025, 1:00 PM
Zai Lab announces Q3 2025 financial results and pipeline updates
ZLAB
Earnings
Guidance Update
Product Launch
- Zai Lab reported total revenues of $116.1 million for Q3 2025, a 14% year-over-year increase, while the adjusted loss from operations narrowed to ($28 million).
- The company maintained a strong cash position of $817.2 million as of September 30, 2025.
- Key product performance highlights include continued strong growth for NUZYRA and increased market penetration for VYVGART/VYVGART Hytrulo, despite softer ZEJULA sales due to competitive dynamics.
- Pipeline advancements include Zoci's rapid progression for SCLC, Povetacicept receiving FDA Breakthrough Designation for IgA nephropathy in September 2025, and anticipated NMPA approval for KarXT in early 2026.
Nov 6, 2025, 1:00 PM
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
ZLAB
Earnings
Guidance Update
Product Launch
- Zai Lab reported total revenues of $116.1 million for the third quarter of 2025, marking a 14% year-over-year growth.
- The company's operating loss improved by 28% year-over-year to $48.8 million (GAAP) and 42% to $28.0 million on an adjusted basis in Q3 2025.
- Full-year 2025 total revenue guidance has been revised to at least $460 million.
- A global registrational study for zocilurtatug pelitecan (zoci, DLL3 ADC) was initiated in October 2025 for second-line+ extensive-stage small cell lung cancer.
- KarXT was included in China's national-level treatment guidelines, with launch preparations underway.
Nov 6, 2025, 12:04 PM
Quarterly earnings call transcripts for Zai Lab.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more